Blackout period ended but new CEO still not buying. Dumped from the All Ords Index. No long-touted DEP drug deal. Three terminated programs with AstraZeneca. Final and unequivocal FDA rejection of VivaGel NDA. Still no partner for VivaGel for Europe. Failed post-market Viraleze clinical trial. No new DEP drugs entering the clinic since 2019. Pathetically poor revenue from marketed products.
Is it finally time to cry and admit that this company has been nothing but a destroyer of shareholder wealth?
My entry price this time around is 12.5 cents but I am in no rush to add more. In fact possibly changing sentiment to sell very soon on the back of the latest no-licence fee and no-milestone fee ‘deal’ with vulture capitalists Medicxi.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)